Skip to Main Content

A Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Patients With HPV+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Conditions

Esophagus | Larynx | Lip, Oral Cavity and Pharynx | Thyroid | Phase I

Phase I

What is the purpose of this trial?

This is a multi center, open-label, phase 1 dose escalation and expansion study evaluating the safety, anti-tumor effect, and immunogenicity of CUE-101 in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).

  • Trial with
    Cue Biopharma, Inc.
  • Start Date
    12/16/2019
  • End Date
    07/29/2019
Trial Image

For more information about this study, contact:

Melissa Perrotti

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    06/22/2020
  • Study HIC
    #2000026098